Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Sitagliptin (trade name: Januvia), a DPP4 inhibitor, increases the expression of tumor suppressors genes, such as  TIMP3, CCM3/KRIT1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 19/June/2017, 10.45 pm

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]

Lifespan- and healthspan-extension therapy: Shikonin, isolated from zicao/purple groomwell, may increase life span via up-regulation of its target gene BubR1 and others, 19/June/2018, 10.42 pm

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the […]

Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin and Aspalathin (SMA) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 19/June/2017, 10.36 pm

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, 80802, Munich, Germany; and Mount Sinai, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA shows that […]

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Cluster of differentiation (CD-30) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via down regulation of its target gene, 19/June/2018, 10.30

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost […]

Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing  Lovastatin, Lofepiramine, AUY922,  Temozolomide, Salinomycin, 5-Fluro-2’deoxycytidine (LLATSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/June/2018, 10.24 pm

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA; and Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine, Los Angeles, California, USA shows that “Cytoplasmic […]

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Sitagliptin (trade name: Januvia), a DPP4 inhibitor, increases the expression of tumor suppressors genes, such as  p53, TA-p73 and TA-p63, BTG2 and INK4a, and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 16/June/2017, 11.48 pm

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]